2023 Q4 Form 10-Q Financial Statement

#000095017023057424 Filed on November 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2023 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.24M $15.26M $9.290M
YoY Change -63.9% 19.26%
% of Gross Profit
Research & Development $38.86M $41.60M $32.77M
YoY Change -57.64% 84.49% 39.27%
% of Gross Profit
Depreciation & Amortization $166.0K $172.0K $170.0K
YoY Change -42.76% 13.33%
% of Gross Profit
Operating Expenses $50.10M $56.86M $42.06M
YoY Change -59.23% 85.82% 34.33%
Operating Profit -$56.86M -$42.06M
YoY Change 85.82%
Interest Expense $5.646M $3.838M $3.560M
YoY Change 23.79% 356.41%
% of Operating Profit
Other Income/Expense, Net -$104.0K $3.837M -$40.00K
YoY Change -125.68% 205.01% -125.0%
Pretax Income -$108.5M -$53.03M -$38.54M
YoY Change -17.14% 26.9%
Income Tax $268.0K
% Of Pretax Income
Net Earnings -$108.7M -$53.03M -$38.54M
YoY Change -16.94% 80.71% 26.9%
Net Earnings / Revenue
Basic Earnings Per Share -$1.14 -$1.28
Diluted Earnings Per Share -$0.71 -$1.14 -$0.25
COMMON SHARES
Basic Shares Outstanding 152.7M 46.69M 30.13M
Diluted Shares Outstanding 46.69M 30.13M

Balance Sheet

Concept 2023 Q4 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $454.0M $509.6M $324.2M
YoY Change 22.07% -1.01%
Cash & Equivalents $374.0M $412.3M $204.2M
Short-Term Investments $79.94M $97.28M $120.0M
Other Short-Term Assets $23.36M $15.50M $11.80M
YoY Change 53.67% -4.07%
Inventory
Prepaid Expenses
Receivables
Other Receivables $939.0K $668.0K
Total Short-Term Assets $478.3M $525.7M $336.6M
YoY Change 23.28% -1.12%
LONG-TERM ASSETS
Property, Plant & Equipment $6.858M $1.934M $8.700M
YoY Change 184.45% -10.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.845M $9.913M $9.900M
YoY Change -58.11% 5.32%
Other Assets $1.213M $1.213M $4.800M
YoY Change -58.36% 17.07%
Total Long-Term Assets $17.92M $19.01M $23.40M
YoY Change -53.2% 0.86%
TOTAL ASSETS
Total Short-Term Assets $478.3M $525.7M $336.6M
Total Long-Term Assets $17.92M $19.01M $23.40M
Total Assets $496.2M $544.7M $360.0M
YoY Change 16.41% -0.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $337.0K $2.229M $8.200M
YoY Change -95.28% 173.33%
Accrued Expenses $24.64M $23.35M $17.80M
YoY Change 113.55% -0.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.11M $29.12M $26.10M
YoY Change 5.97% 13.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.008M $2.933M $3.700M
YoY Change -64.77% -33.93%
Total Long-Term Liabilities $2.008M $2.933M $3.700M
YoY Change -64.77% -33.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.11M $29.12M $26.10M
Total Long-Term Liabilities $2.008M $2.933M $3.700M
Total Liabilities $27.12M $32.06M $29.80M
YoY Change -7.75% 4.93%
SHAREHOLDERS EQUITY
Retained Earnings -$703.4M -$594.7M
YoY Change 50.46%
Common Stock $1.173B $1.108B
YoY Change 5370.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $469.1M $512.7M -$513.5M
YoY Change
Total Liabilities & Shareholders Equity $496.2M $544.7M $360.0M
YoY Change 16.41% -0.99%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$108.7M -$53.03M -$38.54M
YoY Change -16.94% 80.71% 26.9%
Depreciation, Depletion And Amortization $166.0K $172.0K $170.0K
YoY Change -42.76% 13.33%
Cash From Operating Activities -$51.44M -$47.78M -$31.02M
YoY Change -8.35% 16.7%
INVESTING ACTIVITIES
Capital Expenditures $4.634M $33.00K $0.00
YoY Change 2989.33% -100.0%
Acquisitions
YoY Change
Other Investing Activities $18.31M $23.85M $24.08M
YoY Change 107.61% -126.49%
Cash From Investing Activities $13.68M $23.81M $24.08M
YoY Change 57.75% -126.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -481.0K 232.0M 290.0K
YoY Change -100.42% -86.06%
NET CHANGE
Cash From Operating Activities -51.44M -47.78M -31.02M
Cash From Investing Activities 13.68M 23.81M 24.08M
Cash From Financing Activities -481.0K 232.0M 290.0K
Net Change In Cash -38.25M 208.1M -6.650M
YoY Change -157.47% -94.25%
FREE CASH FLOW
Cash From Operating Activities -$51.44M -$47.78M -$31.02M
Capital Expenditures $4.634M $33.00K $0.00
Free Cash Flow -$56.08M -$47.81M -$31.02M
YoY Change -0.36% 15.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001885522
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1274
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41802
dei Entity Registrant Name
EntityRegistrantName
NEUMORA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4367680
dei Entity Address Address Line1
EntityAddressAddressLine1
490 Arsenal Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
760-0900
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NMRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
152703316
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
412284000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
240943000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
97281000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
130941000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16170000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16021000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
525735000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
387955000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
9913000
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
23511000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1934000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2411000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5954000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8231000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1213000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2913000
CY2023Q3 us-gaap Assets
Assets
544749000
CY2022Q4 us-gaap Assets
Assets
426234000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2229000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7147000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23347000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11536000
CY2023Q3 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
149000
CY2022Q4 nmra Early Exercise Liability Current Portion
EarlyExerciseLiabilityCurrentPortion
1644000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3398000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3370000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29123000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23697000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2745000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5072000
CY2023Q3 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
188000
CY2022Q4 nmra Early Exercise Liability Net Of Current Portion
EarlyExerciseLiabilityNetOfCurrentPortion
628000
CY2023Q3 us-gaap Liabilities
Liabilities
32056000
CY2022Q4 us-gaap Liabilities
Liabilities
29397000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
843687000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1107693000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21430000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-311000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-774000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594704000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-467509000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
512693000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
544749000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
426234000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41601000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22549000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103855000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68226000
nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
13000000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15263000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8053000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34239000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23926000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
56864000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
30602000
us-gaap Operating Expenses
OperatingExpenses
138094000
us-gaap Operating Expenses
OperatingExpenses
105152000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-56864000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30602000
us-gaap Operating Income Loss
OperatingIncomeLoss
-138094000
us-gaap Operating Income Loss
OperatingIncomeLoss
-105152000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
3838000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1406000
us-gaap Investment Income Net
InvestmentIncomeNet
10965000
us-gaap Investment Income Net
InvestmentIncomeNet
2276000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-148000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3837000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1258000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10899000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2394000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29344000
us-gaap Net Income Loss
NetIncomeLoss
-127195000
us-gaap Net Income Loss
NetIncomeLoss
-102758000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-284000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
463000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1154000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52890000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29628000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-126732000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103912000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.83
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46691000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46691000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27646000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27646000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35428000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35428000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26841000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26841000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-446850000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
602000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1282000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
476000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2195000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-35625000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-477920000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
404000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
125000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-150000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2543000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-38543000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-513541000
CY2023Q3 nmra Conversion Of Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Value
ConversionOfConvertiblePreferredStockIntoCommonStockUponInitialPublicOfferingValue
843687000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
226618000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1511000
CY2023Q3 nmra Sale And Issuance Of Common Stock
SaleAndIssuanceOfCommonStock
810000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
47000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
137000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6451000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
512693000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-325221000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
606000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-178000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1654000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-43042000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-366017000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2022Q2 nmra Issuance Of Common Stock Value As Noncash Consideration Related To An Acquisition Of Assets
IssuanceOfCommonStockValueAsNoncashConsiderationRelatedToAnAcquisitionOfAssets
24000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
340000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-692000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1751000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-30372000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-394708000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
86000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-284000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2101000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29344000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-422001000
us-gaap Profit Loss
ProfitLoss
-127195000
us-gaap Profit Loss
ProfitLoss
-102758000
nmra Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
13000000
us-gaap Share Based Compensation
ShareBasedCompensation
11189000
us-gaap Share Based Compensation
ShareBasedCompensation
5506000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3068000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
243000
nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
2469000
nmra Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
1323000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
502000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
447000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-261000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-54000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-227000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3274000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1561000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-7623000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1331000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1863000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8646000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8651000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2490000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1045000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111836000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84530000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
89000000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
178274000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
13000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
139783000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31779000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
73000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
488000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50710000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-159983000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
232565000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2517000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2616000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
810000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
87244000
nmra Repurchase Of Unvested Early Exercised Shares
RepurchaseOfUnvestedEarlyExercisedShares
491000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2984000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
950000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232417000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88910000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
171291000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-155603000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
242206000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
409372000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
413497000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
253769000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
412284000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
252509000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
1213000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
1260000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
413497000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
253769000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
843687000
nmra Offering Costs Related To Initial Public Offering Included In Accounts Payable And Accrued Liabilities
OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities
2963000
nmra Offering Costs Related To Initial Public Offering Included In Accounts Payable And Accrued Liabilities
OfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedLiabilities
184000
CY2023Q3 nmra Number Of Clinical And Preclinical Neuroscience Programs
NumberOfClinicalAndPreclinicalNeurosciencePrograms
7
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
7.8463-for-1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on management’s knowledge about current events and expectations about actions the Company may undertake in the future. These judgments, estimates and assumptions are used for, but not limited to, accrued research and development expenses, accounting for acquisitions of assets, fair value of certain assets and liabilities, the fair value of the Company’s convertible preferred stock, the fair value of the Company’s common stock, stock-based compensation, the measurement of right-of-use assets and lease liabilities and related incremental borrowing rate, and uncertain tax positions and the valuation allowance for net deferred tax assets. Actual results may differ from the Company’s estimates.</span></p>
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2900000
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
497039000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
6000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
317000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
496728000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
97281000
CY2023Q3 nmra Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
9913000
CY2023Q3 nmra Estimated Fair Value Of Available For Sale Debt Securities Fair Value
EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue
107194000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
338579000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
775000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
337805000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
130941000
CY2022Q4 nmra Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
23511000
CY2022Q4 nmra Estimated Fair Value Of Available For Sale Debt Securities Fair Value
EstimatedFairValueOfAvailableForSaleDebtSecuritiesFairValue
154452000
CY2023Q3 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1
CY2023Q3 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
13950000
CY2022Q4 nmra Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
13484000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1552000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1618000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
668000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
919000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16170000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16021000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9581000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8400000
CY2023Q3 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
5497000
CY2022Q4 nmra Accrued Clinical Trial And Preclinical Costs
AccruedClinicalTrialAndPreclinicalCosts
652000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3870000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1187000
CY2023Q3 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
4024000
CY2022Q4 nmra Accrued Research And Development Services
AccruedResearchAndDevelopmentServices
889000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
375000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
408000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23347000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11536000
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
820349000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
104417000
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
104417000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
843687000
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
856756000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29734000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6451000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2101000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11189000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5506000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-53027000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29344000
us-gaap Net Income Loss
NetIncomeLoss
-127195000
us-gaap Net Income Loss
NetIncomeLoss
-102758000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46691000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46691000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27646000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27646000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35428000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35428000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26841000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26841000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.14
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.14
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.83
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16233000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
116334000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
nmra-20230930_cal.xml Edgar Link unprocessable
0000950170-23-057424-index-headers.html Edgar Link pending
0000950170-23-057424-index.html Edgar Link pending
0000950170-23-057424.txt Edgar Link pending
0000950170-23-057424-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img234928740_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nmra-20230930.htm Edgar Link pending
nmra-20230930.xsd Edgar Link pending
nmra-ex31_1.htm Edgar Link pending
nmra-ex31_2.htm Edgar Link pending
nmra-ex32_1.htm Edgar Link pending
nmra-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
nmra-20230930_def.xml Edgar Link unprocessable
nmra-20230930_pre.xml Edgar Link unprocessable
nmra-20230930_lab.xml Edgar Link unprocessable
nmra-20230930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending